Specialty Pharmacy Segment Growth Persists for Biopharm Manufacturers and BDI Pharma

Share Article

Over the past several years, the pharmaceutical industry has come to recognize the significant value that specialty pharmacies provide to patients and prescribers, alike. As a result, the pipelines of these same manufacturers are filled with products, each in various phases of study, which will be relying on this new class of trade to dispense, or administer, and monitor to ensure that the greatest efficacy can be derived from the use of their particular biopharmaceutical drugs.

BDI Pharma's Columbia, SC Headquarters

Identifying the unique and individual needs of our varied customer base is what has defined and continues to define BDI Pharma as an organization that can both effectively and rapidly adapt to the ever-changing biopharm landscape.

Over the past several years, the pharmaceutical industry has come to recognize the significant value that specialty pharmacies provide to patients and prescribers, alike. With that recognition has come the realization by Big Pharma that this class of pharmacy, the fastest growing sector of healthcare provider, also affords a manufacturer with tremendous value in the critical areas of compliance and persistency – criteria that truly define whether or not a drug impacts the patient as intended, thus providing the prescriber with the outcome that was promised. As a result, the pipelines of these same manufacturers are filled with products, each in various phases of study, which will be relying on this new class of trade to dispense, or administer, and monitor to ensure that the greatest efficacy can be derived from the use of their particular biopharmaceutical drugs.

As identified by its name, a specialty pharmacy is predicated on the delivery of “specialty pharmaceuticals”, many also labeled as biopharmaceuticals, to a patient as prescribed by a physician. The interaction of the specialty pharmacy with its customers and referral sources is generally far more substantial and requires the capability to offer more of a “high touch”, personal level of service than that which is provided by many other alternate site pharmacy services. BDI Pharma, Inc. (BDI), the nation's fastest growing national distributor of specialty biotherapeutics and an organization established to specifically deliver “high touch” service, continues to demonstrate recurring growth in distribution and promotional programs associated with this class of trade.

“Identifying the unique and individual needs of our varied customer base is what has defined and continues to define BDI Pharma as an organization that can both effectively and rapidly adapt to the ever-changing biopharm landscape,” stated Edward Stiefel, Co-Founder and Co-President of BDI. “Being willing to truly listen to both our customers and our manufacturing partners, then take that knowledge and implement our strategies and programs, BDI has been able to offer product access, market relevant data and industry education that has proven vital to the continued growth and expansion of many specialty pharmacies throughout the country.”

Additional resources and information regarding BDI Pharma’s service offerings can be found at http://www.ivig.com.

About BDI Pharma, Inc.

Since 1995, BDI Pharma has defined its customer-centric approach to serving the nation's healthcare community through innovative supply solutions, unparalleled customer service, extensive product knowledge, 24/7 emergency availability and urgent-need delivery. An open-access resource for reference material, educational literature, market data and online ordering, bdipharma.com (ivig.com) has become an industry-renowned point of reference. Proprietary programs for comprehensive reimbursement services -- bdiaccess.com; specialty veterinarians -- 4legpharma.com; product consignment -- consignadvantage.com; resources for flu vaccine and general vaccines/immunologics -- securivax.com; and purchasing programs -- securigam.com and qoreprogram.com round out a family of solutions tailored to the needs of the healthcare community at large.

BDI Pharma’s portfolio includes IVIG, branded and generic specialty pharmaceuticals, chemotherapy products, vaccines, albumin, coagulation factors, high-titer or “hyper” immune globulins, and other specialty injectables. BDI Pharma is recognized as an “ADR,” or Authorized Distributor of Record, for all of the manufacturers it represents.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brad Davis
Visit website